suma/proline

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention comprises certain proline derivatives which are useful as human leukocyte elastase inhibitors, e.g. in the treatment of tissue degenerative diseases such as pulmonary emphysema, atherosclerosis, rheumatoid and osteo

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention comprises certain proline derivatives which are useful as human leukocyte elastase inhibitors, e.g. in the treatment of tissue degenerative diseases such as pulmonary emphysema, atherosclerosis, rheumatoid and osteo

FIELD OF THE INVENTION This invention relates to nucleic acid and amino acid sequences of a novel acidic proline-rich protein and to the use of these sequences in the diagnosis, prevention, and treatment of inflammation and disorders associated with abnormal cell proliferation. BACKGROUND OF THE

FIELD OF THE INVENTION The present invention relates to novel compounds derived from N-(benzenesulfonyl)-(L)-proline, to the process for their preparation and to their use in therapeutics. These novel compounds have an antagonistic action towards bradykinin and are useful in therapeutics,

FIELD OF THE INVENTION The present disclosure relates to antimicrobial agents and methods of using. More particularly, the disclosure relates to antimicrobial peptides and therapeutic uses thereof. SEQUENCE LISTING This application contains a sequence listing in paper format and in computer readable

FIELD OF THE INVENTION The present disclosure relates to antimicrobial agents and methods of using. More particularly, the disclosure relates to antimicrobial peptides and therapeutic uses thereof. SEQUENCE LISTING This application contains a sequence listing in paper format and in computer readable

FIELD OF THE INVENTION The present invention relates to a process for producing trans-4-hydroxy-L-proline. Trans-4-hydroxy-L-proline is useful as a starting compound for medicines and an additive to foods. The present invention also relates to a novel enzyme capable of catalyzing the hydroxylation

FIELD OF THE INVENTION The present invention relates to novel compounds derived from N-(benzenesulfonyl)-(L)-proline, to the process for their preparation and to their use in therapeutics. These novel compounds have an antagonistic action towards bradykinin and are useful in therapeutics,

FIELD OF THE INVENTION The present invention relates to novel compounds derived from N-benzenesulfonyl-L-proline, to the process for their preparation and to their use in therapeutics. These novel compounds have an inhibitory action on bradykinin and are useful in therapeutics, particularly for the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to recombinant aprotinin variants; processes to prepare the described peptide variants as homogeneously processed secretion products with transformed yeasts, and medicaments containing the recombinant aprotinin

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to recombinant aprotinin variants; processes to prepare the described peptide variants as homogeneously processed secretion products with transformed yeasts, and medicaments containing the recombinant aprotinin

FIELD The present disclosure concerns a novel organocatalyst, more particularly a proline mimetic organocatalyst, that is particularly useful for facilitating asymmetric syntheses, particularly enantioselective and diastereoselective reactions. BACKGROUND Since the early days of enantioselective

FIELD OF THE INVENTION This invention relates to a novel plasminogen activator constructed by using recombinant DNA technology, a deoxyribonucleic acid (DNA) coding for the activator, a recombinant plasmid containing the DNA, a microbial or animal cell transformed with the recombinant plasmid, and a

FIELD OF THE INVENTION This invention relates to a novel plasminogen activator constructed by using recombinant DNA technology, a deoxyribonucleic acid (DNA) coding for the activator, a recombinant plasmid containing the DNA, a microbial or animal cell transformed with the recombinant plasmid, and a

The present invention relates to a method for producing a pharmaceutically active peptide compound, which contains L-m-sarcolysine as the amino acid component. The active substance serves particularly for chemotherapy against cancers and is used especially for melanomas. In using a carrier substance